AXIM BIOTECHNOLOGIES, INC. Contracts & Agreements
35 Contracts & Agreements
- Business Finance (27 contracts)
- Business Operations (2)
- Human Resources (1)
- Uncategorized (5)
- Description of Securities (Filed With SEC on April 16, 2024)
- Form of Stock Purchase Agreement dated March 15, 2024 (Filed With SEC on March 21, 2024)
- Form of Version 3 Note dated March 15, 2024 (Filed With SEC on March 21, 2024)
- Form of Version 2 Note dated March 15, 2024 (Filed With SEC on March 21, 2024)
- Form of Version 1 Note dated March 15, 2024 (Filed With SEC on March 21, 2024)
- Form of Convertible Note Purchase Agreement dated March 15, 2024 (Filed With SEC on March 21, 2024)
- EXHIBIT A FORM OF NOTE (Filed With SEC on December 28, 2023)
- CONVERTIBLE NOTE PURCHASE AGREEMENT (Filed With SEC on December 28, 2023)
- EQUITY PURCHASE AGREEMENT (Filed With SEC on June 2, 2023)
- CONVERTIBLE NOTE (Filed With SEC on May 30, 2023)
- CONSULTING AGREEMENT (Filed With SEC on May 25, 2023)
- Description of Securities (Filed With SEC on April 17, 2023)
- Convertible Note Modification and Default Waiver Agreement (Filed With SEC on January 27, 2023)
- SETTLEMENT AGREEMENT (Filed With SEC on January 27, 2023)
- Convertible Notes Modification and Default Waiver Agreement (Filed With SEC on January 27, 2023)
- Certain identified information has been excluded from this exhibit because it is both notmaterialand is the type that theregistranttreats as private or confidential. (Filed With SEC on September 19, 2022)
- STOCK PURCHASE AGREEMENT (Filed With SEC on August 29, 2022)
- STOCK PURCHASE AGREEMENT (Filed With SEC on August 29, 2022)
- EQUITY PURCHASE AGREEMENT (Filed With SEC on August 2, 2022)
- Termination Agreement dated March 3, 2022, by and between AXIM Biotechnologies, Inc. and Empowered Diagnostics, LLC (Filed With SEC on April 15, 2022)
- Description of Securities (Filed With SEC on April 15, 2022)
- Binding Term Sheet Agreement dated August 3, 2021, by and between AXIM Biotechnologies, Inc. and Advanced Tear Diagnostics, LLC (Filed With SEC on April 15, 2022)
- Asset Purchase Agreement dated August 26, 2021, by and between AXIM Biotechnologies, Inc. and Advanced Tear Diagnostics, LLC (Filed With SEC on April 15, 2022)
- AXIM BIOTECHNOLOGIES, INC. 6% CONVERTIBLE REDEEMABLE NOTE DUE SEPTEMBER 29, 2022 (Filed With SEC on February 16, 2022)
- CONVERTIBLE NOTE (Filed With SEC on February 16, 2022)
- PROMISSORY NOTE (Filed With SEC on February 16, 2022)
- EQUITY PURCHASE AGREEMENT (Filed With SEC on May 14, 2021)
- EQUITY PURCHASE AGREEMENT (Filed With SEC on May 14, 2021)
- AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT (Filed With SEC on December 17, 2019)
- PREFERRED STOCK PURCHASE AGREEMENT (Filed With SEC on February 26, 2019)
- DEBT EXCHANGE AGREEMENT (Filed With SEC on December 7, 2018)
- CONVERTIBLE PROMISSORY NOTE (Filed With SEC on December 7, 2018)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 7, 2018)
- STOCK PURCHASE AGREEMENT (Filed With SEC on April 18, 2018)
- AXIM Biotechnologies, Inc. 18 E 50th St 5th Floor New York, NY 10022 (Filed With SEC on May 23, 2016)
